WO2001044280A3 - Methods and compositions for the manufacture of replication incompetent adenovirus - Google Patents

Methods and compositions for the manufacture of replication incompetent adenovirus Download PDF

Info

Publication number
WO2001044280A3
WO2001044280A3 PCT/US2000/033123 US0033123W WO0144280A3 WO 2001044280 A3 WO2001044280 A3 WO 2001044280A3 US 0033123 W US0033123 W US 0033123W WO 0144280 A3 WO0144280 A3 WO 0144280A3
Authority
WO
WIPO (PCT)
Prior art keywords
replication
replication incompetent
cell lines
present
particles
Prior art date
Application number
PCT/US2000/033123
Other languages
French (fr)
Other versions
WO2001044280A2 (en
Inventor
Vaughn B Himes
Siyamak Rasty
Richard W Peluso
Original Assignee
Genovo Inc
Vaughn B Himes
Siyamak Rasty
Richard W Peluso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genovo Inc, Vaughn B Himes, Siyamak Rasty, Richard W Peluso filed Critical Genovo Inc
Priority to EP00980987A priority Critical patent/EP1238091A2/en
Priority to CA002393844A priority patent/CA2393844A1/en
Priority to AU18174/01A priority patent/AU1817401A/en
Priority to JP2001544769A priority patent/JP2003516743A/en
Publication of WO2001044280A2 publication Critical patent/WO2001044280A2/en
Publication of WO2001044280A3 publication Critical patent/WO2001044280A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Abstract

The present invention relates to complementing cell lines for the production of replication incompetent viruses, which significantly reduce or eliminate the presence of replication competent viruses. Methods to make and use the complementing cell lines are also provided, as are nucleic acid molecules, polynucleotides, and vectors for making the cell lines. In particular, the present invention relates to complementing cell lines for the production of replication incompetent adenoviruses (Ad), which significantly reduce or eliminate the presence of replication competent Ad (RCA) and can serve for the large scale production of infectious replication incompetent adenovirus particles that may be used for the treatment of human patients as for example in gene therapy. The present invention further relates to an assay for detecting the presence of replication competent virus particles, in particular RCA, in a stock of infectious replication incompetent virus particles, in particular replication incompetent adenovirus particles, which employs a real time quantitative PCR assay with a sensitivity level to detect one replication competent virus particle per ≥ 109 replication incompetent virus particles.
PCT/US2000/033123 1999-12-14 2000-12-07 Methods and compositions for the manufacture of replication incompetent adenovirus WO2001044280A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00980987A EP1238091A2 (en) 1999-12-14 2000-12-07 Methods and compositions for the manufacture of replication incompetent adenovirus
CA002393844A CA2393844A1 (en) 1999-12-14 2000-12-07 Methods and compositions for the manufacture of replication incompetent adenovirus
AU18174/01A AU1817401A (en) 1999-12-14 2000-12-07 Methods and compositions for the manufacture of replication incompetent adenovirus
JP2001544769A JP2003516743A (en) 1999-12-14 2000-12-07 Methods and compositions for the production of replication incompetent adenovirus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17055099P 1999-12-14 1999-12-14
US60/170,550 1999-12-14
US19626600P 2000-04-11 2000-04-11
US60/196,266 2000-04-11

Publications (2)

Publication Number Publication Date
WO2001044280A2 WO2001044280A2 (en) 2001-06-21
WO2001044280A3 true WO2001044280A3 (en) 2001-11-29

Family

ID=26866208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033123 WO2001044280A2 (en) 1999-12-14 2000-12-07 Methods and compositions for the manufacture of replication incompetent adenovirus

Country Status (5)

Country Link
EP (1) EP1238091A2 (en)
JP (1) JP2003516743A (en)
AU (1) AU1817401A (en)
CA (1) CA2393844A1 (en)
WO (1) WO2001044280A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
EP1327688A1 (en) * 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
WO2004057035A2 (en) * 2002-12-20 2004-07-08 Qbiogene Inc. Method and kit for detecting replication competent adenoviruses
WO2009006300A2 (en) * 2007-06-28 2009-01-08 Advantagene, Inc. Production cell lines for adenoviral manufacturing
US8346485B2 (en) 2008-11-25 2013-01-01 Quest Diagnostics Investments Incorporated Methods and apparatuses for estimating initial target nucleic acid concentration in a sample by modeling background signal and cycle-dependent amplification efficiency of a polymerase chain reaction
CA3103367A1 (en) * 2018-06-13 2019-12-19 The Council Of The Queensland Institute Of Medical Research Viral detection assay
US20190292609A1 (en) * 2019-05-30 2019-09-26 Trizell Ltd. Gene Therapy Vector Contamination Assay
WO2023039243A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013399A1 (en) * 1993-11-12 1995-05-18 The Public Health Research Institute Of The City Of New York, Inc. Hybridization probes for nucleic acid detection, universal stems, methods and kits
EP0745690A2 (en) * 1995-05-12 1996-12-04 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide Probes, Assays and Kits
WO1997015679A1 (en) * 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
WO1998013499A2 (en) * 1996-09-25 1998-04-02 Novartis Ag Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013399A1 (en) * 1993-11-12 1995-05-18 The Public Health Research Institute Of The City Of New York, Inc. Hybridization probes for nucleic acid detection, universal stems, methods and kits
EP0745690A2 (en) * 1995-05-12 1996-12-04 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide Probes, Assays and Kits
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997015679A1 (en) * 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
WO1998013499A2 (en) * 1996-09-25 1998-04-02 Novartis Ag Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HERISSE J ET AL: "NUCLEOTIDE SEQUENCE OF ADENOVIRUS 2 DNA FRAGMENT ENCODING FOR THE CARBOXYLIC REGION OF THE FIBER PROTEIN AND THE ENTIRE E4 REGION", NUCLEIC ACIDS RESEARCH,GB,IRL PRESS LTD., OXFORD, vol. 9, no. 16, 25 August 1981 (1981-08-25), pages 4023 - 4042, XP002051626, ISSN: 0305-1048 *

Also Published As

Publication number Publication date
AU1817401A (en) 2001-06-25
WO2001044280A2 (en) 2001-06-21
CA2393844A1 (en) 2001-06-21
EP1238091A2 (en) 2002-09-11
JP2003516743A (en) 2003-05-20

Similar Documents

Publication Publication Date Title
Challberg et al. Initiation of adenovirus DNA replication: detection of covalent complexes between nucleotide and the 80-kilodalton terminal protein
Caradonna et al. Induction of uracil-DNA glycosylase and dUTP nucleotidohydrolase activity in herpes simplex virus-infected human cells.
HUP0003331A2 (en) Method for the production of non-group c adenoviral vectors
WO2001042504A3 (en) Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
GB2375113A (en) Virus strains
WO2005030121A3 (en) Compounds, compositions and methods
WO2001005945A3 (en) Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) Gene therapy
DK1783225T3 (en) Structural protein from AAV, its preparation and use
Carter et al. Autoregulation of adenovirus type 5 early gene expression II. Effect of temperature-sensitive early mutations on virus RNA accumulation
ATE454468T1 (en) DETECTION OF THE INSTABILITY OF MICROSATELLITES AND USE THEREOF IN TUMOR DIAGNOSIS
WO2002022879A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2001044280A3 (en) Methods and compositions for the manufacture of replication incompetent adenovirus
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
CA2281895A1 (en) Ikb kinases
WO2001057058A3 (en) Detection of differential gene expression
Guarino et al. In vitro activity of the baculovirus late expression factor LEF-5
Lee et al. Oncolytic potential of E1B 55 kDa‐deleted YKL‐1 recombinant adenovirus: Correlation with p53 functional status
WO2003099859A3 (en) Novel use of adenoviruses and nucleic acids coding therefor
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO2004050680A3 (en) Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
WO2002078526A3 (en) Cancer-testis antigens
WO2002096939A3 (en) Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO1999053087A3 (en) 5'-modified nucleotides and the application thereof in molecular biology and medicine
WO2001036679A3 (en) METHODS FOR GENERATING SINGLE STRANDED cDNA FRAGMENTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2393844

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 544769

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000980987

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000980987

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000980987

Country of ref document: EP